Q3 2022
Released Nov 1, 2022, before the open
10-Q filed Nov 9, 2022, 38 days after period end · 0000078003-22-000101
Q3 2022 · 10-Q
Revenue$22.64B$22.64B −5.8% vs Q3 2021−18.4% vs Q2 2022
Net Income$8.61B$8.61B +5.7% vs Q3 2021−13.1% vs Q2 2022
EPS Diluted$1.51$1.51 +6.3% vs Q3 2021−12.7% vs Q2 2022
Operating Cash Flowderived$5,974,000,000−44.8%
Free Cash Flowderived$5,133,000,000−49.7%
Margins · derived
Net margin38.0%+4.1 pt vs Q3 2021
What the release said
The release
Same quarter
| Metric | Q3 2022 | Q3 2021 | Q3 2020 | Q3 2019 |
|---|---|---|---|---|
| Revenue | $22.64B | $24.04B | $10.28B | $12.68B |
| Net Income | $8.61B | $8.15B | $1.47B | $7.68B |
| EPS Diluted | $1.51 | $1.42 | $0.26 | $1.36 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pfizer Inc · CIK 78003 · Engraved from SEC EDGAR